NCT03614689View on ClinicalTrials.gov

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Active, not recruitingOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

November 25, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

December 31, 2024

Conditions
Ovarian Cancer
Trial Locations (6)

Unknown

Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sichuan Cancer Hospital, Chengdu

Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

Peking Union Medical College Hospital, Beijing

Peking University International Hospital, Beijing

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

lead

Geneplus-Beijing Co. Ltd.

INDUSTRY

NCT03614689 - Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire | Biotech Hunter | Biotech Hunter